You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Details for New Drug Application (NDA): 020779

✉ Email this page to a colleague

NDA 020779 describes VIRACEPT, which is a drug marketed by Agouron Pharms and is included in three NDAs. It is available from one supplier. Additional details are available on the VIRACEPT profile page.

The generic ingredient in VIRACEPT is nelfinavir mesylate. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the nelfinavir mesylate profile page.

Summary for 020779

Tradename:	VIRACEPT
Applicant:	Agouron Pharms
Ingredient:	nelfinavir mesylate
Patents:	0

Pharmacology for NDA: 020779

Mechanism of Action	Cytochrome P450 3A Inhibitors HIV Protease Inhibitors

Medical Subject Heading (MeSH) Categories for 020779

HIV Protease Inhibitors

Suppliers and Packaging for NDA: 020779

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
VIRACEPT	nelfinavir mesylate	TABLET;ORAL	020779	NDA	AGOURON	63010-010	63010-010-30	300 TABLET, FILM COATED in 1 BOTTLE (63010-010-30)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	EQ 250MG BASE
Approval Date:	Mar 14, 1997	TE:		RLD:	Yes

Expired US Patents for NDA 020779

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Agouron Pharms	VIRACEPT	nelfinavir mesylate	TABLET;ORAL	020779-001	Mar 14, 1997	⤷ Start Trial	⤷ Start Trial
Agouron Pharms	VIRACEPT	nelfinavir mesylate	TABLET;ORAL	020779-001	Mar 14, 1997	⤷ Start Trial	⤷ Start Trial
Agouron Pharms	VIRACEPT	nelfinavir mesylate	TABLET;ORAL	020779-001	Mar 14, 1997	⤷ Start Trial	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.